Trials / Completed
CompletedNCT00301002
Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis
A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (planned)
- Sponsor
- The Guenther Dermatology Research Centre · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Alefacept is effective in the treatment of palmar plantar pustulosis.
Detailed description
Palmar plantar pustulosis is a chronic, disabling skin condition which is difficult to treat since it is often recalcitrant to current treatments and associated with high recurrence rates. This condition appears to be a T lymphocyte mediated condition and is thought by some to be a subtype of psoriasis. Alefacept affects T cell activation and induces apoptosis of memory T cells. It has been shown to be efficacious in the treatment of psoriasis vulgaris and may be associated with prolonged remissions. There is extremely limited experience with use of Alefacept in Palmar Plantar Pustulosis. This pilot trial should provide additional information concerning its use for this indication.
Conditions
- Psoriasis
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Pustulosis of Palms and Soles
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alefacept |
Timeline
- Start date
- 2005-06-01
- Completion
- 2006-10-01
- First posted
- 2006-03-10
- Last updated
- 2006-11-23
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00301002. Inclusion in this directory is not an endorsement.